Topical Resiquimod 0.01% Gel Decreases Herpes Simplex Virus Type 2 Genital Shedding: A Randomized, Controlled Trial
The Journal of Infectious Diseases2007Vol. 195(9), pp. 1324–1331
Citations Over TimeTop 10% of 2007 papers
Karen E. Mark, Lawrence Corey, Tze‐Chiang Meng, Amalia Magaret, Meei‐Li Huang, Stacy Selke, Herbert B. Slade, Stephen K. Tyring, Terri Warren, Stephen L. Sacks, Peter A. Leone, Vicki A. Bergland, Anna Wald
Abstract
These findings suggest that the immunological control of HSV-2 reactivation and lesion clearance may differ and that TLR7 and TLR8 agonists can reduce the frequency of mucosal HSV-2 reactivation.
Related Papers
- → Understanding viral shedding of severe acute respiratory coronavirus virus 2 (SARS-CoV-2): Review of current literature(2020)117 cited
- → HSV shedding(2004)81 cited
- → Prolonged viral shedding and antibody persistence in patients with COVID-19(2021)32 cited
- → Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection(2021)27 cited
- → Prolonged Viral Shedding in Vertically Acquired SARS-CoV-2 Infection in Preterm Infants–Shedding Versus Infectivity(2021)